Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207


Preclinical ex vivo evaluation of the diagnostic performance of a new device for in situ label-free fluorescence spectral analysis of breast masses.

Mathieu MC, Toullec A, Benoit C, Berry R, Validire P, Beaumel P, Vincent Y, Maroun P, Vielh P, Alchab L, Farcy R, Moniz-Koum H, Fontaine-Aupart MP, Delaloge S, Balleyguier C.

Eur Radiol. 2018 Jan 5. doi: 10.1007/s00330-017-5228-7. [Epub ahead of print]


Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C; BERENICE Study Group.

Ann Oncol. 2017 Dec 15. doi: 10.1093/annonc/mdx773. [Epub ahead of print]


Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis.

Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.

Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.


Steroid hormone profiling in human breast adipose tissue using semi-automated purification and highly sensitive determination of estrogens by GC-APCI-MS/MS.

Hennig K, Antignac JP, Bichon E, Morvan ML, Miran I, Delaloge S, Feunteun J, Le Bizec B.

Anal Bioanal Chem. 2018 Jan;410(1):259-275. doi: 10.1007/s00216-017-0717-8. Epub 2017 Nov 16.


Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.


Value of whole breast magnetic resonance elastography added to MRI for lesion characterization.

Balleyguier C, Lakhdar AB, Dunant A, Mathieu MC, Delaloge S, Sinkus R.

NMR Biomed. 2018 Jan;31(1). doi: 10.1002/nbm.3795. Epub 2017 Oct 26.


Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?

Daroles J, Borget I, Suciu V, Mazouni C, Delaloge S, Balleyguier C.

Eur J Cancer. 2017 Nov;85:23-30. doi: 10.1016/j.ejca.2017.08.002. Epub 2017 Sep 4.


Targeting PI3K/AKT pathway in triple-negative breast cancer.

Delaloge S, DeForceville L.

Lancet Oncol. 2017 Oct;18(10):1293-1294. doi: 10.1016/S1470-2045(17)30514-4. Epub 2017 Aug 8. No abstract available.


Patient satisfaction with a rapid diagnosis of suspicious breast lesions: Association with distress and anxiety.

Boinon D, Dauchy S, Charles C, Fasse L, Cano A, Balleyguier C, Mazouni C, Caron H, Vielh P, Delaloge S.

Breast J. 2018 Mar;24(2):154-160. doi: 10.1111/tbj.12856. Epub 2017 Jul 13.


Tumor characteristics and family history in relation to mammographic density and breast cancer: The French E3N cohort.

Maskarinec G, Dartois L, Delaloge S, Hopper J, Clavel-Chapelon F, Baglietto L.

Cancer Epidemiol. 2017 Aug;49:156-160. doi: 10.1016/j.canep.2017.07.003. Epub 2017 Jul 8.


Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

Pivot X, Fumoleau P, Pierga JY, Delaloge S, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulié P, Jacquin JP, Lavau-Denes S, Kerbrat P, Cox D, Faure-Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G.

Eur J Cancer. 2017 Aug;81:151-160. doi: 10.1016/j.ejca.2017.05.020. Epub 2017 Jun 16.


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P.

N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. Erratum in: N Engl J Med. 2017 Oct 26;377(17 ):1700.


Pattern of relapse in low-risk breast cancer patients followed within a community care network.

Agopian A, Dubot C, Houzard S, Savignoni A, Fridmann S, Odier A, Fourquet A, Fourchotte V, Dehghani C, Nos C, Delaloge S, Zongo N, Cottu P.

Breast J. 2017 Nov;23(6):687-693. doi: 10.1111/tbj.12821. Epub 2017 May 27.


Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.

Ghouadni A, Delaloge S, Lardelli P, Kahatt C, Byrski T, Blum JL, Gonçalves A, Campone M, Nieto A, Alfaro V, Cullell-Young M, Lubinski J.

Breast. 2017 Aug;34:18-23. doi: 10.1016/j.breast.2017.04.006. Epub 2017 Apr 30.


Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects?

Bailleux C, André F, Delaloge S.

Eur J Cancer. 2017 May;77:153-154. doi: 10.1016/j.ejca.2017.03.016. Epub 2017 Apr 8. No abstract available.


Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.

Giacchetti S, Hamy AS, Delaloge S, Brain E, Berger F, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Saghatchian M, Lerebours F, Mazouni C, Tembo O, Espié M, Reyal F, Marty M, Asselain B, Pierga JY.

Eur J Cancer. 2017 Apr;75:323-332. doi: 10.1016/j.ejca.2017.01.008. Epub 2017 Mar 7.


Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.

Riet FG, Fayard F, Arriagada R, Santos MA, Bourgier C, Ferchiou M, Heymann S, Delaloge S, Mazouni C, Dunant A, Rivera S.

Eur J Cancer. 2017 May;76:45-51. doi: 10.1016/j.ejca.2017.01.022. Epub 2017 Mar 6.


[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Nov;103(11):951-952. doi: 10.1016/j.bulcan.2016.10.009. Epub 2016 Oct 28. French. No abstract available.


New oral targeted therapies for metastatic breast cancer disrupt the traditional patients' management-A healthcare providers' view.

Martin E, Pourtau L, Di Palma M, Delaloge S.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12624. Epub 2016 Dec 27.


Routinely collected data may usefully supplement randomised controlled data on treatment effects for mortality.

Pérol D, Robain M, Delaloge S, Cailliot C.

BMJ. 2016 Dec 16;355:i6745. doi: 10.1136/bmj.i6745. No abstract available.


The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.

Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, Humeau J, Buque A, Kepp O, Zitvogel L, André F, Mathieu MC, Delaloge S, Kroemer G.

Oncoimmunology. 2016 Aug 18;5(10):e1218106. eCollection 2016.


Reply to 'The potential and perils of observational studies' by M. Buyse et al.

Delaloge S, Pérol D, Robain M, Cailliot C.

Ann Oncol. 2017 Feb 1;28(2):436-437. doi: 10.1093/annonc/mdw572. No abstract available.


A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).

Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S.

Ann Oncol. 2017 Feb 1;28(2):313-320. doi: 10.1093/annonc/mdw562.


Extended anti-HER2 therapy in early breast cancer: longer beats shorter?

Refae S, Pistilli B, Delaloge S.

Curr Opin Oncol. 2016 Nov;28(6):469-475. Review.


The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic.

Delaloge S, Bonastre J, Borget I, Garbay JR, Fontenay R, Boinon D, Saghatchian M, Mathieu MC, Mazouni C, Rivera S, Uzan C, André F, Dromain C, Boyer B, Pistilli B, Azoulay S, Rimareix F, Bayou el-H, Sarfati B, Caron H, Ghouadni A, Leymarie N, Canale S, Mons M, Arfi-Rouche J, Arnedos M, Suciu V, Vielh P, Balleyguier C.

Eur J Cancer. 2016 Oct;66:131-7. doi: 10.1016/j.ejca.2016.06.021. Epub 2016 Aug 26.


70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.


Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.

Rodriguez C, Suciu V, Poterie A, Lacroix L, Miran I, Boichard A, Delaloge S, Deneuve J, Azoulay S, Mathieu MC, Valent A, Michiels S, Arnedos M, Vielh P.

Mol Oncol. 2016 Nov;10(9):1430-1436. doi: 10.1016/j.molonc.2016.07.009. Epub 2016 Aug 5.


Jusqu'où aller dans les désescalades thérapeutiques en chirurgie et radiothérapie du cancer du sein infiltrant ?

Delaloge S.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S90-1. doi: 10.1016/S0007-4551(16)30150-3. French. No abstract available.


[Breast cancer screening: On our way to the future].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Lorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Review. French.


Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C.

Ann Oncol. 2016 Sep;27(9):1725-32. doi: 10.1093/annonc/mdw260. Epub 2016 Jul 19.


A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G.

Nat Commun. 2016 Jul 13;7:12222. doi: 10.1038/ncomms12222.


Added Value of Contrast-Enhanced Spectral Mammography in Postscreening Assessment.

Tardivel AM, Balleyguier C, Dunant A, Delaloge S, Mazouni C, Mathieu MC, Dromain C.

Breast J. 2016 Sep;22(5):520-8. doi: 10.1111/tbj.12627. Epub 2016 Jun 27.


Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

Awada A, Cortés J, Martín M, Aftimos P, Oliveira M, López-Tarruella S, Espie M, Lardelli P, Extremera S, Fernández-García EM, Delaloge S.

Clin Breast Cancer. 2016 Oct;16(5):364-371. doi: 10.1016/j.clbc.2016.05.005. Epub 2016 May 14.


Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Le Guillou M, Perrault de Jotemps M, Chauvet MP, Chaouat M, Pujol P, Feunteun J, Delaloge S, Forgez P, Gompel A.

Oncotarget. 2016 Jul 19;7(29):45317-45330. doi: 10.18632/oncotarget.9638.


The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.

Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, Poillot ML, Arveux P, Delaloge S, Andre F, Zitvogel L, Kroemer G.

Autophagy. 2016 May 3;12(5):864-75. doi: 10.1080/15548627.2016.1154244. Epub 2016 Mar 16.


The current use and attitudes towards tumor genome sequencing in breast cancer.

Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart MJ, Sotiriou C, Ignatiadis M, Azim HA Jr.

Sci Rep. 2016 Mar 2;6:22517. doi: 10.1038/srep22517.


Whole exome sequencing of rare aggressive breast cancer histologies.

Dieci MV, Smutná V, Scott V, Yin G, Xu R, Vielh P, Mathieu MC, Vicier C, Laporte M, Drusch F, Guarneri V, Conte P, Delaloge S, Lacroix L, Fromigué O, André F, Lefebvre C.

Breast Cancer Res Treat. 2016 Feb;156(1):21-32. doi: 10.1007/s10549-016-3718-y. Epub 2016 Feb 23.


Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.


Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.

Dartois L, Fagherazzi G, Baglietto L, Boutron-Ruault MC, Delaloge S, Mesrine S, Clavel-Chapelon F.

Int J Cancer. 2016 May 15;138(10):2415-27. doi: 10.1002/ijc.29987. Epub 2016 Feb 4.


A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.

Blum JL, Gonçalves A, Efrat N, Debled M, Conte P, Richards PD, Richards D, Lardelli P, Nieto A, Cullell-Young M, Delaloge S.

Breast Cancer Res Treat. 2016 Jan;155(2):295-302. doi: 10.1007/s10549-015-3675-x. Epub 2016 Jan 9.


SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.

Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, Baselga J.

Breast Cancer Res Treat. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. Epub 2015 Nov 4.


Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G.

Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.


Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries.

Saghatchian M, Fadoukhair Z, Hofert K, Lanoy E, Mathieu MC, Mazouni C, Delaloge S.

Breast J. 2016 Jan-Feb;22(1):96-100. doi: 10.1111/tbj.12525. Epub 2015 Oct 28.


Diagnostic Performance of MR-guided Vacuum-Assisted Breast Biopsy: 8 Years of Experience.

Ferré R, Ianculescu V, Ciolovan L, Mathieu MC, Uzan C, Canale S, Delaloge S, Dromain C, Balleyguier C.

Breast J. 2016 Jan-Feb;22(1):83-9. doi: 10.1111/tbj.12519. Epub 2015 Oct 28.


Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer.

Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C, Prada N, Poirier-Colame V, Chaba K, Arnould L, Ghiringhelli F, Fumoleau P, Spielmann M, Delaloge S, Poillot ML, Arveux P, Goubar A, Andre F, Zitvogel L, Kroemer G.

Autophagy. 2015;11(10):1878-90. doi: 10.1080/15548627.2015.1082022.


Laparoendoscopic Single-site Surgery (LESS) for Prophylactic Salpingo-oophorectomy Improves Cosmetic Satisfaction Compared to Standard Laparoscopy.

Miailhe G, Dauchy S, Bentivegna E, Gouy S, Charles C, Delaloge S, Morice P, Uzan C.

Anticancer Res. 2015 Nov;35(11):6105-10.


Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS.

Ann Oncol. 2015 Dec;26(12):2505-6. doi: 10.1093/annonc/mdv478. Epub 2015 Oct 13. No abstract available.


Breast pain and imaging.

Balleyguier C, Arfi-Rouche J, Haddag L, Canale S, Delaloge S, Dromain C.

Diagn Interv Imaging. 2015 Oct;96(10):1009-16. doi: 10.1016/j.diii.2015.08.002. Epub 2015 Oct 2.


[Molecular signatures of breast cancer: What clinical utility?].

Delaloge S, Saghatchian M, Ghouadni A, Fekih M, André F.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S102-5. doi: 10.1016/S0007-4551(15)31227-3. French.


Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F.

Ann Oncol. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. No abstract available.

Supplemental Content

Loading ...
Support Center